ArticleBlood advances2024

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL.

Adam S Kittai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.